Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.09
At close: Jun 18 EDT
$3.09
0.000.00%
Pre-Market: 7:56 AM EDT
Comments
Loading...
Aldeyra Therapeutics Analyst Ratings and Price Targets | NASDAQ:ALDX | Benzinga
Aldeyra Therapeutics Inc has a consensus price target of $9.25 based on the ratings of 5 analysts. The high is $10 issued by HC Wainwright & Co. on May 19, 2025. The low is $8 issued by Citigroup on October 17, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and HC Wainwright & Co. on May 19, 2025, April 7, 2025, and April 4, 2025, respectively. With an average price target of $9.67 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 212.84% upside for Aldeyra Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Oppenheimer
Citigroup
1calculated from analyst ratings
Analyst Ratings for Aldeyra Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/19/2025 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | 191.26% | BTIG | Thomas Shrader40% | $11 → $9 | Maintains | Buy | Get Alert |
| 04/04/2025 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 223.62% | Oppenheimer | Francois Brisebois39% | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | Buy Now | 223.62% | Oppenheimer | Francois Brisebois39% | → $10 | Upgrade | Perform → Outperform | Get Alert |
| 04/02/2024 | Buy Now | 223.62% | HC Wainwright & Co. | Matthew Caufield39% | → $10 | Reinstates | Buy → Buy | Get Alert |
| 10/17/2023 | Buy Now | 158.9% | Citigroup | Yigal Nochomovitz54% | $25 → $8 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | — | Oppenheimer | Justin Kim36% | — | Downgrade | Outperform → Perform | Get Alert |
| 08/09/2023 | Buy Now | 353.07% | Oppenheimer | Justin Kim36% | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 385.44% | HC Wainwright & Co. | Matthew Caufield39% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 385.44% | HC Wainwright & Co. | Matthew Caufield39% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 385.44% | HC Wainwright & Co. | Matthew Caufield39% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/01/2023 | Buy Now | 709.06% | Citigroup | Yigal Nochomovitz54% | $28 → $25 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 385.44% | HC Wainwright & Co. | Matthew Caufield39% | → $15 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 806.15% | Citigroup | Yigal Nochomovitz54% | $23 → $28 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 385.44% | HC Wainwright & Co. | Matthew Caufield39% | → $15 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 385.44% | HC Wainwright & Co. | Matthew Caufield39% | → $15 | Reiterates | → Buy | Get Alert |
| 11/21/2022 | Buy Now | 644.34% | Citigroup | Yigal Nochomovitz54% | $26 → $23 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Aldeyra Therapeutics (ALDX) stock?
The latest price target for Aldeyra Therapeutics (NASDAQ:ALDX) was reported by HC Wainwright & Co. on May 19, 2025. The analyst firm set a price target for $10.00 expecting ALDX to rise to within 12 months (a possible 223.62% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aldeyra Therapeutics (ALDX)?
The latest analyst rating for Aldeyra Therapeutics (NASDAQ:ALDX) was provided by HC Wainwright & Co., and Aldeyra Therapeutics reiterated their buy rating.
When was the last upgrade for Aldeyra Therapeutics (ALDX)?
The last upgrade for Aldeyra Therapeutics Inc happened on April 3, 2024 when Oppenheimer raised their price target to $10. Oppenheimer previously had a perform for Aldeyra Therapeutics Inc.
When was the last downgrade for Aldeyra Therapeutics (ALDX)?
The last downgrade for Aldeyra Therapeutics Inc happened on October 17, 2023 when Oppenheimer changed their price target from N/A to N/A for Aldeyra Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aldeyra Therapeutics (ALDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aldeyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aldeyra Therapeutics was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
Is the Analyst Rating Aldeyra Therapeutics (ALDX) correct?
While ratings are subjective and will change, the latest Aldeyra Therapeutics (ALDX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Aldeyra Therapeutics (ALDX) is trading at is $3.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
